摘要
目的：观测消风散加味对慢性持续期支气管哮喘呼出气一氧化氮浓度（fractional concentration of exhaled nitricoxide,FeNO）,血浆P物质（substance P,SP）和血管活性肠肽（vasoactive intestinal peptide,VIP）含量的影响,探讨其治疗支气管哮喘的可能作用机制。方法：选取符合纳入标准的支气管哮喘患者80例,随机分为对照组和治疗组。对照组给予布地奈德福莫特罗粉吸入剂（160μg/4.5μg）,早晚各2吸。治疗组在对照组治疗的基础之上给予消风散加味,每日1剂。两组疗程均为1个月。观察治疗前后两组患者肺功能相关指标第1秒末用力呼气量（forced expiratory volume in first second,FEV1）,第1秒末用力呼气量占用力肺活量百分比（percentage of forced expiratory volume in first second and forced vital capacity,FEV1/FVC）,1 s用力呼气量占预计值百分比（percentage of forced expiratory volume in first second and its predicted value,FEV1%）,呼气流量峰值变异率（variety ratio of peak expiratory flow,PEF）,FeNO,血浆SP,VIP水平变化,并记录两组患者不良反应。结果：治疗后两组患者肺功能指标FEV1,FEV1/FVC,FEV1%比较,治疗组均高于对照组（P〈0.05）;PEF变异率比较,治疗组低于对照组（P〈0.05）;治疗后治疗组患者FeNO,血浆SP水平均低于对照组（P〈0.05）,治疗组VIP水平高于对照组（P〈0.05）;两组患者不良反应总发生率比较,治疗组低于对照组（P〈0.05）。结论：消风散加味联合布地奈德福莫特罗粉吸入剂治疗支气管哮喘与单用布地奈德福莫特罗粉吸入剂治疗相比较,可更有效改善支气管哮喘患者的肺功能,调节神经源性气道炎症水平,同时降低不良反应发生率,值得推广应用。
Objective： To observe the effect of modified Xiaofengsan on fractional concentration of exhaled nitricoxide（FeNO）,substance P（SP） and vasoactive intestinal peptide（VIP） in plasma of patients with persistent asthma. Method： Totally 80 cases in line with the inclusion criteria were collected and randomly divided into control group and treatment group. Patients in control group were given Budesonide/formoterol（160 μg/4. 5 μg）,while patients in treatment group were given modified Xiaofengsan combined with Budesonide/formoterol for 1 months. Before and after treatment,forced expiratory volume in first second（FEV1）,percentage of forced expiratory volume in first second and forced vital capacity（FEV1/FVC）,percentage of forced expiratory volume in first second and its predicted value（FEV1%）,variety ratio of peak expiratory flow,FeNO and the levels of SP and VIP in plasma were measured respectively. The adverse reactions of the two groups were recorded at the same time. Result： Compared with control group,FEV1,FEV1/FVC,FEV1%,VIP in plasma in treatment group were higher（P〈0. 05）,while PEF variety ratio,FeNO and the level of SP in plasma were lower（P〈0. 05）after treatment. Compared with control group,the incidence rate of the adverse reactions in treatment group was lower（P〈0. 05）. Conclusion： Modified Xiaofengsan combined with Budesonide/formoterol is more effective than Budesonide/formoterol in improving pulmonary function, regulating the neurogenic airway inflammation and lowering the incidence rate of the adverse reactions. It is worth promotion and application.
作者
贾琳
武蕾
郭洁
观云
JIA Lin;WU Lei;GUO Jie;GUAN Yun(Hebei Province Hospital of Traditional Chinese Medicine,Shijiazhuang 050031,China)
出处
《中国实验方剂学杂志》
CAS
CSCD
北大核心
2018年第22期148-152,共5页
Chinese Journal of Experimental Traditional Medical Formulae
基金
河北省科技计划项目(16277726D)
河北省中医药管理局课题项目(2016032)
河北省中医药类重大医学科研课题项目(zyzd2013001)
关键词
支气管哮喘
P物质
血管活性肠肽
呼出气一氧化氮浓度
中医治疗
bronchial asthma
substance P （SP）
vasoactive intestinal peptide （VIP）
fractionalconcentration of exhaled nitricoxide （FeNO）
traditional Chinese treatment
作者简介
贾琳，博士，副主任医师，副教授，从事中西医结合治疗呼吸系统疾病研究，E-mail：17661650@qq．com;[通信作者]武蕾，主任医师，教授，从事中西医结合治疗支气管哮喘研究，E-mail：5634200@qq．com
